!
!
!
Options thérapeutiques :
Le traitement de la perte osseuse et la prévention des complications osseuses constituent une part
importante de la prise en charge des métastases osseuses. Les diverses options thérapeutiques qui sont
offertes doivent donc faire l’objet de discussions entre le médecin et le patient.
Actuellement, les métastases osseuses sont traitées au moyen d’une classe de médicaments appelés
bisphosphonates15. Il a été démontré que ces agents retardent ou préviennent l’apparition des
complications osseuses16,17.
Il n’existe encore aucun traitement approuvé visant à prévenir ou à retarder l’apparition des métastases
osseuses, mais des études sur de nouvelles options thérapeutiques sont en cours.
-30-
Références
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl):1588-1594.
2 Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients’ quality
of life, mobility, and functional independence. Support Care Cancer. 2008;16:879-889.
3 Weinfurt KP, Anstrom KJ, Castel JD, Schulman KA, Saad F. Effects of zoledronic acid on pain
associated with bone metastasis in patients with prostate cancer. Ann Oncol. 2006;17:986-989.
4 Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80(suppl): 1588-1594.
5 Rosen LS, Gordon D, Tchekmedyian NS et al. Nonsmall cell lung carcinoma and other solid tumors.
Cancer. 2004;100:2613-2621.
6 Gralow J, Tripathy, D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom
Manage. 2007;33:462-472.
7 http://www.cancer.org/Cancer/BoneMetastasis/OverviewGuide/bone-metastasis-overview-diagnosed.
Dernière consultation le 16 novembre 2010.
8 Lipton A, Theriault RL, Hortobagyi GN. Pamidronate prevents skeletal complications and is effective
palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer
2000;88:1082-1090.
9 Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlated with
reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-1867.
10 Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events,
bone metástasis and survival of prostate cancer: a population based cohort study in Denmark (1999
to 2007). J Urol 2010; 184:162-167.
11 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with
osteoporotic fractures. Osteoporos Int 2006;17:1726-1733.
12 Saad F, Gleason DM, Murray R et al. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in
Patients With Hormone-Refractory MetastaticProstate Carcinoma. Journal Ntl Cancer Inst
2002;19:1458-1468.
13 Schulman K et Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;
109(11):2334-2342.
14 Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients’ quality
of life, mobility, and functional independence. Support Care Cancer. 2008; 16: 879-889.
15 Mortimer JE, Schulman K, Kohles JD.Patterns of bisphosponate use in the United States in the
treatment of metastatic bone disease. Clin Breast Cancer 2007; 7(9):682-689.
16 Saad F. Impact of bone metastases on patient’s quality of life and importance of treatment. Eur Urol.
2006;5(suppl 5):547-550.
17 Gralow J, Tripathy, D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom
Manage. 2007;33:462-472.